Strategic Asset Sale Turn Biotechnologies recently divested assets to Klotho Neurosciences for a $300M global pharma partnership, signaling openness to collaboration and potential co-development or licensing opportunities with large partners.

Licensing Momentum Active licensing agreements with HanAll Biopharma for ERA technology to develop eye and ear therapies indicate a strong partner appetite and potential for expanded collaborations in specialty disease areas leveraging Turn's epigenetic reprogramming approach.

Delivery Platform Launch of the novel eTurna delivery platform positions Turn to offer nucleic acid therapeutics capabilities; potential sales angle includes enabling partners with advanced delivery for mRNA and rejuvenation therapies.

LeadershipDepth Strategic hires in leadership and research, including a veteran CFO and a renowned head of research, suggest increased investor and partner confidence, making Turn a viable co-development or strategic partner for funding, milestones, and joint programs.

Clinical and Ophthalmic Focus Recent collaborations target ophthalmic and otic indications, presenting clear entry points for BD discussions around eye and ear disease programs, cross-licensing, and expansion into adjacent rejuvenation indications.